SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...

Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

CORONADO, Calif. — Despite recent advances in the treatment of cutaneous squamous cell carcinoma (SCC), a lack of consensus ...